Seeking Alpha

Buy the rumor, sell the news: after a 3 week rally, Optimer Pharmaceutical (OPTR -7.2%) sells...

Buy the rumor, sell the news: after a 3 week rally, Optimer Pharmaceutical (OPTR -7.2%) sells off hard after winning FDA approval for its antibiotic drug Dificid for treatment of Clostridium Difficel-Associated infections.
Comments (1)
  • HIGHWATER 888
    , contributor
    Comments (317) | Send Message
     
    Comment? I'm looking for some insight. All I can say with certainty is that someone began heavy selling at 3:26 PM. The FDA approval was all good. Did someone push the stop loss orders? Did a hedge fund misread the FDA approval? After market trading regained most of the lost ground, but still below the key $14 BB.

     

    Either I'm misreading the FDA approval, or OPTR became crazy cheap for about 20 minutes on Friday. IMO, OPTR, post approval is worth $17-18 per share but will be watching the price action closely on Tuesday.
    29 May 2011, 12:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs